Holen Sie sich die Stockscreener-App
3.99
4.32%
-0.18
Handel nachbörslich:
4.08
0.09
+2.26%
Schlusskurs vom Vortag:
$4.17
Offen:
$4.18
24-Stunden-Volumen:
1.37M
Relative Volume:
0.39
Marktkapitalisierung:
$426.43M
Einnahmen:
$234.04M
Nettoeinkommen (Verlust:
$-323.92M
KGV:
-0.8808
EPS:
-4.53
Netto-Cashflow:
$-223.46M
1W Leistung:
+15.65%
1M Leistung:
-24.57%
6M Leistung:
+32.12%
1J Leistung:
-45.12%
1-Tages-Spanne:
$3.98
$4.185
1-Wochen-Bereich:
$3.42
$4.365
52-Wochen-Spanne:
$2.30
$9.745
Revance Therapeutics Inc Stock (RVNC) Company Profile
Firmenname
Revance Therapeutics Inc
Sektor
Branche
Telefon
(615) 724-7755
Adresse
1222 DEMONBREUN STREET, NASHVILLE, CA
Vergleichen Sie RVNC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| RVNC | 3.99 | 426.43M | 234.04M | -323.92M | -223.46M | -4.53 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Revance Therapeutics Inc Stock (RVNC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-16 | Hochstufung | Exane BNP Paribas | Underperform → Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-22 | Eingeleitet | Goldman | Buy |
| 2021-10-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-15 | Bestätigt | Needham | Buy |
| 2020-08-11 | Fortgesetzt | Mizuho | Buy |
| 2020-03-23 | Herabstufung | Goldman | Buy → Neutral |
| 2019-12-02 | Eingeleitet | Goldman | Buy |
| 2019-10-30 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-02-15 | Eingeleitet | Wells Fargo | Market Perform |
| 2019-02-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-01-29 | Eingeleitet | Stifel | Buy |
| 2018-11-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2018-09-17 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-04-20 | Bestätigt | Mizuho | Buy |
| 2018-03-27 | Eingeleitet | Needham | Buy |
| 2018-03-05 | Eingeleitet | Goldman | Buy |
| 2018-01-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2017-12-06 | Eingeleitet | Guggenheim | Buy |
| 2017-12-06 | Bestätigt | Mizuho | Buy |
| 2017-11-27 | Eingeleitet | Barclays | Overweight |
| 2017-11-17 | Eingeleitet | Mizuho | Buy |
| 2017-08-22 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Revance Therapeutics Inc Aktie (RVNC) Neueste Nachrichten
LMR Partners LLP Acquires New Shares in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated by Analysts at StockNews.com - MarketBeat
Neurotoxin Market Overall Study Report 2024-2032 | Revance - openPR
Revance, Crown Labs Again Extend Tender Offer Start Deadline - MarketWatch
Revance Therapeutics jumps after Crown Laboratories tender offer extended again - MSN
Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives $9.66 Consensus Target Price from Analysts - MarketBeat
StockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ROIC, PWUP, RVNC on Behalf of Shareholders - GlobeNewswire Inc.
Where are the Opportunities in (RVNC) - Stock Traders Daily
Revance Therapeutics (NASDAQ:RVNC) Given Hold Rating at Needham & Company LLC - MarketBeat
Revance Therapeutics' (RVNC) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat
Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Lags Revenue Estimates - MSN
Revance Therapeutics Reports Q3 Growth Amid Merger Plans - TipRanks
Revance Therapeutics sinks amid `going concern' disclosure - MSN
Revance Therapeutics Q3 2024 Earnings: EPS of -$0.37 Beats Estimate, Revenue of $59.9M Misses Expectations - GuruFocus.com
Revance Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Revance Q3 Revenue Up 11% to $59.9M Amid Crown Merger Deal; China Approves DAXXIFY | RVNC Stock News - StockTitan
Top 10 startups in Dermatology in Bay Area, United States in Nov, 2024 - Tracxn
Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com - MarketBeat
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RVNC, CPTN, RCM on Behalf of Shareholders - Stockhouse Publishing
Revance Therapeutics revises Teoxane agreement, expands distribution to ANZ By Investing.com - Investing.com Canada
Traders Buy High Volume of Put Options on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
Revance Therapeutics' (RVNC) "Hold" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Revance Therapeutics revises Teoxane agreement, expands distribution to ANZ - Investing.com
Revance Therapeutics (NASDAQ:RVNC) Shares Gap UpHere's What Happened - MarketBeat
Crown Settles Customer Dispute To Close $924M Revance Buy - Law360
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - Benzinga
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments” - Barchart
Revance Therapeutics surges after Crown tender offer extended, settles with Teoxane - MSN
Revance Shares Rise Premarket on Teoxane Settlement, Tender Extension - MarketWatch
Revance Therapeutics, Inc. and Teoxane SA Enters into the Sixth Amendment to the Exclusive Distribution Agreement - Marketscreener.com
Revance Therapeutics drops as deadline for Crown Lab tender set to expire - MSN
Revance Therapeutics (NASDAQ:RVNC) Shares Down 3.8%Should You Sell? - MarketBeat
Revance Therapeutics extends merger offer date amid Teoxane talks - Investing.com India
Revance Therapeutics extends merger offer date amid Teoxane talks By Investing.com - Investing.com Australia
Revance Therapeutics, Crown Labs Again Extend Tender Offer Deadline - MarketWatch
Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc.RVNC - PR Newswire
The Law Offices of Frank R. Cruz Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors - Business Wire
(RVNC) Trading Signals - Stock Traders Daily
StockNews.com Initiates Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
Law Offices of Howard G. Smith Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors - Marketscreener.com
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors - Business Wire
Revance Therapeutics, Inc. (NASDAQ:RVNC) Short Interest Up 25.0% in September - MarketBeat
AQR Capital Management LLC Has $517,000 Stake in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
Algert Global LLC Sells 127,260 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
M&A Took A Holiday In Q3, With Decreased Volume And Value - Citeline
Finanzdaten der Revance Therapeutics Inc-Aktie (RVNC)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):